Apellis Pharms Drug Patent Portfolio
Apellis Pharms owns 2 orange book drugs protected by 13 US patents Given below is the list of Apellis Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844841 | Dosing regimens and related compositions and methods | 09 Dec, 2038 | Active |
| US11040107 | Dosing regimens and related compositions and methods | 09 Apr, 2038 | Active |
| US11903994 | Dosing regimens | 22 Feb, 2037 | Active |
| US10035822 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | 15 Nov, 2033 | Active |
| US10875893 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | 15 Nov, 2033 | Active |
| US11292815 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | 15 Nov, 2033 | Active |
| US10125171 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | 02 Aug, 2033 | Active |
| US11661441 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | 13 Jan, 2033 | Active |
| US7888323 | Potent compstatin analogs | 04 Dec, 2027 | Active |
| US7989589 | Compstatin analogs with improved activity | 04 Dec, 2027 | Active |
| US9169307 | Potent compstatin analogs | 18 Nov, 2027 | Active |
| US8168584 | Methods of treating age-related macular degeneration by compstatin and analogs thereof | 07 Apr, 2027 | Active |
| US9056076 | Method of treating age-related macular degeneration comprising administering a compstatin analog | 25 Oct, 2026 | Active |
Latest Legal Activities on Apellis Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Apellis Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Jul, 2024 | US10875893 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 May, 2024 | US10875893 |
| Sequence Moved to Public Database | 20 Feb, 2024 | US11903994 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903994 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Feb, 2024 | US11903994 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11903994 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903994 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903994 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Feb, 2024 | US11903994 |
|
Email Notification
Critical
| 01 Feb, 2024 | US11903994 |
|
Issue Notification Mailed
Critical
| 31 Jan, 2024 | US11903994 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10035822 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10125171 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10875893 |
|
Application Is Considered Ready for Issue
Critical
| 22 Jan, 2024 | US11903994 |
Apellis Pharms's Family Patents
Apellis Pharms drugs have patent protection in a total of 25 countries. It's US patent count contributes only to 30.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Apellis Pharms Drug List
Given below is the complete list of Apellis Pharms's drugs and the patents protecting them.
1. Empaveli
Empaveli is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844841 | Dosing regimens and related compositions and methods |
09 Dec, 2038
(14 years from now)
| Active |
| US11040107 | Dosing regimens and related compositions and methods |
09 Apr, 2038
(13 years from now)
| Active |
| US10035822 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US10875893 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US11292815 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US10125171 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
02 Aug, 2033
(8 years from now)
| Active |
| US11661441 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
13 Jan, 2033
(8 years from now)
| Active |
| US7888323 | Potent compstatin analogs |
04 Dec, 2027
(3 years from now)
| Active |
| US7989589 | Compstatin analogs with improved activity |
04 Dec, 2027
(3 years from now)
| Active |
| US9169307 | Potent compstatin analogs |
18 Nov, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Empaveli's drug page
2. Syfovre
Syfovre is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11903994 | Dosing regimens |
22 Feb, 2037
(12 years from now)
| Active |
| US10035822 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US10875893 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US11292815 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
15 Nov, 2033
(8 years from now)
| Active |
| US10125171 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
02 Aug, 2033
(8 years from now)
| Active |
| US11661441 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
13 Jan, 2033
(8 years from now)
| Active |
| US7888323 | Potent compstatin analogs |
04 Dec, 2027
(3 years from now)
| Active |
| US7989589 | Compstatin analogs with improved activity |
04 Dec, 2027
(3 years from now)
| Active |
| US9169307 | Potent compstatin analogs |
18 Nov, 2027
(2 years from now)
| Active |
| US8168584 | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
07 Apr, 2027
(2 years from now)
| Active |
| US9056076 | Method of treating age-related macular degeneration comprising administering a compstatin analog |
25 Oct, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Syfovre's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List